New research from Wales suggests that children born to mothers with depression during pregnancy face higher risks of neurodevelopmental issues, regardless of antidepressant treatment, highlighting the complex balance between managing maternal depression and child health outcomes.
A large study in Wales has found that children born to mothers who experienced depression during pregnancy were more likely to be diagnosed later with a range of neurodevelopmental difficulties, even when the mothers were treated with antidepressants. The research, published in PLOS Medicine and reported by Kathimerini from an APE-MPE dispatch, followed more than 167,000 children born between 2009 and 2016 and tracked their medical and school records through 2022.
The analysis looked for links between maternal depression, antidepressant use and outcomes such as autism spectrum disorder, attention deficit hyperactivity disorder, learning difficulties, behavioural problems, emotional struggles and social challenges. Children whose mothers had depression but did not take antidepressants had special educational needs in 24 out of every 100 cases, while the figure rose by only three points among those whose mothers used antidepressants. By comparison, the rate was 20 in 100 among children with no recorded exposure to maternal depression or antidepressants during pregnancy.
The researchers said the pattern suggests that prenatal depression itself is associated with higher neurodevelopmental risk, regardless of whether medication was used. At the same time, they cautioned that the apparent additional risk linked with antidepressant treatment could reflect the severity of the mother’s depression, since women with more serious symptoms are more likely to receive drug therapy. That makes it difficult to separate the effect of the illness from the effect of the medicine.
Their conclusion adds to a broader body of research indicating that maternal mental health during pregnancy can matter for child development. Earlier studies have connected antenatal anxiety and depressed mood with poorer cognitive outcomes and differences in early brain development, although findings have not always been consistent. The new work reinforces the importance of monitoring depression in pregnancy, while also underlining that any possible medication risk has to be weighed against the dangers of untreated depression, including a higher chance of postnatal depression.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
